01—Abstract
Summary
Summary of the 10-K filed March 2, 2015. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (filed as Halozyme Therapeutics; ticker HALO) reported total revenues of $75.3 milliona for 2014, up from $54.8 million in 2013, and a net loss of $68.4 million, or $0.56 per share, compared with a net loss of $83.5 million in 2013.
Product sales, net rose to $37.8 millionb, revenues under collaborative agreements were $28.1 million (including a $15.0 million license fee from the Janssen Collaboration), and royalties were $9.4 million. Roche accounted for 57% of 2014 total revenues. Accumulated deficit reached $450.4 million at December 31, 2014.
Management reported cash, cash equivalents and marketable securities of $135.6 millionc and said this is sufficient to fund operations for at least the next twelve months, with anticipated 2015 net cash burn of $35 million to $45 million. The company has refocused its strategy on PEGPH20, an investigational PEGylated hyaluronidase for tumors that accumulate hyaluronic acid, with its lead trial in metastatic pancreatic cancer (Study 109-202) in Phase 2. That trial was placed on clinical hold in April 2014 over a possible difference in thromboembolic event rates and resumed in July 2014 under a revised protocol.
PEGPH20 received FDA Fast Track and Orphan Drug designations. Halozyme plans to pursue collaborations or other strategic alternatives for its diabetes and dermatology programs, and it reduced its workforce by approximately 13%d in November 2014.
Enhanze collaborations with Roche, Baxter, Pfizer and Janssen remain the other core revenue driver, with one product approved in the U.S. and three in Europe. Key risks for investors include dependence on the PEGPH20 program and its thromboembolic safety profile, reliance on a small number of collaborators and contract manufacturers, uncertainty over FDA labeling requirements for Hylenex recombinant in insulin pump use, a $50 million term loan secured by substantially all assets, and a history of losses with no profitability to date.
02—Key points
Key Highlights
- Total revenues rose to $75.3 million in 2014 from $54.8 million in 2013, including a $15.0 million Janssen license fee.
- Net loss narrowed to $68.4 million ($0.56 per share) in 2014 from $83.5 million ($0.74 per share) in 2013.
- Product sales, net increased to $37.8 million from $24.4 million, driven by bulk rHuPH20 supply for Roche collaboration products and Hylenex recombinant sales of $13.2 million.
- Cash, cash equivalents and marketable securities totaled $135.6 million at December 31, 2014; management expects them to fund operations for at least the next twelve months, with 2015 net cash burn estimated at $35 million to $45 million.
- PEGPH20 is the priority program, with Phase 2 pancreatic cancer data showing a 34% objective response rate in the PAG arm of Study 109-202 Stage 1 (versus 23% in the AG arm, P=0.17).
- Roche accounted for 57% of 2014 total revenues, and Janssen for 20%, highlighting customer concentration.
- Accumulated deficit reached $450.4 million, and the company has never been profitable.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2014, Halozyme Therapeutics lost $0.91.
- Revenue$75.3M100.0%
- Cost of revenue−$22.7M30.2%
- Gross profit$52.6M69.8%
- Operating costs−$115.6M153.5%
- Operating income−$63.0M83.7%
- Interest, other & tax−$5.3M7.1%
- Net income−$68.4M90.8%
04—Financials
Financial Highlights
Figures from 10-KFY2014filed March 2, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $75.33M$54.80M | +37.5% |
| Cost of Revenue | $22.73M$6.25M | +263.9% |
| Gross Profit | $52.60M$48.55M | +8.3% |
| R&D Expenses | $79.70M$96.64M | −17.5% |
| SG&A Expenses | $35.94M$32.35M | +11.1% |
| Operating Expenses | $138.37M$135.23M | +2.3% |
| Operating Income | -$63.04M-$80.43M | +21.6% |
| Interest Expense | $5.60M$3.30M | +69.7% |
| Net Income | -$68.38M-$83.48M | +18.1% |
| EPS (Basic) | $-0.56$-0.74 | +24.3% |
| Shares Outstanding (Basic) | 122.69M112.81M | +8.8% |
05—Questions
Frequently Asked Questions
Why did the net loss decline in 2014?
Net loss decreased to $68.4 million from $83.5 million in 2013. Total revenues rose to $75.3 million, including a $15.0 million license fee from the Janssen Collaboration, and research and development expenses fell to $79.7 million from $96.6 million, largely because Enhanze collaboration costs were reduced by capitalizing manufacturing costs for approved products.
What happened with the PEGPH20 pancreatic cancer trial?
Study 109-202 was placed on clinical hold in April 2014 over a possible difference in thromboembolic event rates between treatment arms. The hold was lifted and enrollment resumed in July 2014 under a revised protocol that adds low molecular weight heparin prophylaxis and excludes higher-risk patients. The company and the data monitoring committee continue to monitor thromboembolic events, and the study may be halted again if the protocol changes do not reduce those events.
How much cash does Halozyme have and how long will it last?
Cash, cash equivalents and marketable securities totaled $135.6 million at December 31, 2014. Management believes this is sufficient to fund operations for at least the next twelve months and anticipates 2015 net cash burn of approximately $35 million to $45 million, though it may need additional financing later.
What are the main risks to the investment case?
The filing highlights reliance on PEGPH20's clinical success and safety profile, dependence on collaborators such as Roche and on contract manufacturers Avid and Cook, uncertainty over FDA requirements for a Hylenex recombinant label update for insulin pump use, and a $50 million term loan secured by substantially all assets. The company also notes it has never been profitable and may need to raise capital, which could dilute shareholders.
06—Continue